Stifel analyst Nathan Jones maintains A.O. Smith (NYSE:AOS) with a Hold and lowers the price target from $59 to $58.
Aurinia Pharmaceuticals Finds No Buyer After Strategic Business Review, Launches Stock Buyback
Aurinia Pharmaceuticals Q4 2023 results: EPS loss $(0.19), sales $45.1 million. AUR200 development halted. Strategic review concludes. $150 million share buyback initiated.